In vivo studies should be carried out for compounds 26 and 27 to investigate their potent cytotoxicity versus FLT3 AML cells, their higher tolerability with no significant toxicity signs, their overall response rate, progression-free survival, and overall survival rate. The gene discussed is FLT3; the disease is acute myeloid leukemia.